BACKGROUND: The aim of the current study was to identify predictors of pathologic complete response (pCR) following neoadjuvant therapy. METHODS: From 2000 to 2007, 518 breast cancer patients received neoadjuvant therapy. Data were compared using chi(2) and Fisher's exact tests and multivariate analysis of variance, as appropriate. RESULTS: Of 518 breast cancer patients receiving neoadjuvant therapy, 81 (16%) had pCR (77 of 456 [17%] with chemotherapy, 4 of 62 [6%] with endocrine therapy; P < .05). Four factors were associated with pCR: higher tumor grade (P = .015), lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P < .0001), HER2/neu amplification (P = .025), and negative lymph node status (P < .0001). On multivariate analysis, ER and PR negativity, HER2/neu amplification, and negative lymph node status were found to significantly correlate with pCR. CONCLUSIONS: Patients with ER-negative and PR-negative and HER2/neu-amplified breast cancer phenotypes are more likely to experience pCR to neoadjuvant therapy. Although pCR is more frequently observed following neoadjuvant chemotherapy, it is rare following neoadjuvant endocrine therapy.
BACKGROUND: The aim of the current study was to identify predictors of pathologic complete response (pCR) following neoadjuvant therapy. METHODS: From 2000 to 2007, 518 breast cancerpatients received neoadjuvant therapy. Data were compared using chi(2) and Fisher's exact tests and multivariate analysis of variance, as appropriate. RESULTS: Of 518 breast cancerpatients receiving neoadjuvant therapy, 81 (16%) had pCR (77 of 456 [17%] with chemotherapy, 4 of 62 [6%] with endocrine therapy; P < .05). Four factors were associated with pCR: higher tumor grade (P = .015), lack of estrogen receptor (ER) and progesterone receptor (PR) expression (P < .0001), HER2/neu amplification (P = .025), and negative lymph node status (P < .0001). On multivariate analysis, ER and PR negativity, HER2/neu amplification, and negative lymph node status were found to significantly correlate with pCR. CONCLUSIONS:Patients with ER-negative and PR-negative and HER2/neu-amplified breast cancer phenotypes are more likely to experience pCR to neoadjuvant therapy. Although pCR is more frequently observed following neoadjuvant chemotherapy, it is rare following neoadjuvant endocrine therapy.
Authors: Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai Journal: Clin Cancer Res Date: 2005-08-15 Impact factor: 12.531
Authors: Roman Rouzier; Lajos Pusztai; Jean-Remi Garbay; Suzette Delaloge; Kelly K Hunt; Gabriel N Hortobagyi; Donald Berry; Henry M Kuerer Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: A Rody; T Karn; R Gätje; A Ahr; C Solbach; K Kourtis; M Munnes; S Loibl; S Kissler; E Ruckhäberle; U Holtrich; G von Minckwitz; M Kaufmann Journal: Breast Date: 2006-09-28 Impact factor: 4.380
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer Journal: JAMA Date: 2006-04-12 Impact factor: 56.272
Authors: Shigeto Ueda; Darren Roblyer; Albert Cerussi; Amanda Durkin; Anais Leproux; Ylenia Santoro; Shanshan Xu; Thomas D O'Sullivan; David Hsiang; Rita Mehta; John Butler; Bruce J Tromberg Journal: Cancer Res Date: 2012-07-09 Impact factor: 12.701
Authors: Bohuslav Melichar; Helena Hornychová; Hana Kalábová; Hana Bašová; Jindřiška Mergancová; Hana Urminská; Pavel Jandík; Vladimír Cervinka; Jan Laco; Aleš Ryška Journal: Med Oncol Date: 2012-03-06 Impact factor: 3.064
Authors: Matthew J Ellis; Vera J Suman; Jeremy Hoog; Li Lin; Jacqueline Snider; Aleix Prat; Joel S Parker; Jingqin Luo; Katherine DeSchryver; D Craig Allred; Laura J Esserman; Gary W Unzeitig; Julie Margenthaler; Gildy V Babiera; P Kelly Marcom; Joseph M Guenther; Mark A Watson; Marilyn Leitch; Kelly Hunt; John A Olson Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Cristina Saura; Ling-Ming Tseng; Stephen Chan; Raju T Chacko; Mario Campone; Alexy Manikhas; Shona M Nag; Cynthia G Leichman; Lokanatha Dasappa; Peter A Fasching; Fernando Hurtado de Mendoza; W Fraser Symmans; David Liu; Pralay Mukhopadhyay; Christine Horak; Guan Xing; Lajos Pusztai Journal: Oncologist Date: 2013-07-12